

Human IL-36β/IL-1F8 Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF1099


DESCRIPTION			
Species Reactivity	Human		
Specificity	Detects human IL-36β/IL-1F8 in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with recombinant human (rh) IL-1β and rhIL-1F6 is observed and less than 1% cross-reactivity with rhIL-1α and rhIL-18 is observed.		
Source	Polyclonal Goat IgG		
Purification	Antigen Affinity-purified		
Immunogen	<i>E. coli</i> -derived recombinant human IL-36β/IL-1F8 Met1-Glu157 Accession # Q3MIH0		
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.		
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.		

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample	
Western Blot	0.1 μg/mL	Recombinant Human IL-36β/IL-1F8 (Catalog # 1099-IL)	
Immunohistochemistry	5-15 μg/mL	Immersion fixed paraffin-embedded sections of human tonsil subjected to Antigen Retrieval Reagent-Basic (Catalog # CTS013)	
Neutralization	Measured by its ability to neutralize IL-36β/IL-1F8-induced IL-8 secretion in human pre-adipocytes. van Asseldor E.J. et al. (2010) Obesity 18:2234. The Neutralization Dose (ND ₅₀) is typically 50-300 ng/mL in the presence of		
	20 ng/mL Recomb	inant Human IL-36β/IL-1F8 (aa 5-157).	
Blockade of Receptor-ligand Interaction	Human IL-1 Rrp2/	ISA, 1.5-6 μg/mL of this antibody will block 50% of the binding of 5 μg/mL of Recombinant IL-1 R6 Fc Chimera (Catalog # 872-RP) to immobilized Recombinant Human IL-36β/IL-1F8 .) coated at 1 μg/mL (100 μL/well). At 100 μg/mL, this antibody will block >90% of the binding.	

DATA



Cell IL-8 Secretion Induced by IL-36B/IL-1F8 and Neutralization by Human IL-36β/ IL-1F8 Antibody. Recombinant Human IL-36β/ IL-1F8 (aa 5-157) (Catalog # 6834-IL) induces IL-8 secretion in human pre-adipocytes in a dosedependent manner (orange line). IL-8 Secretion elicited by Recombinant Human IL-36β/ IL-1F8 (aa 5-157) (20 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL-36β/IL-1F8 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1099). The ND_{50} is typically 50-300 ng/mL.

PREPARATION AND S	TORAGE		
Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.		
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.		
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.		
	 12 months from date of receipt, -20 to -70 °C as supplied. 		
	 1 month, 2 to 8 °C under sterile conditions after reconstitution. 		
	 6 months, -20 to -70 °C under sterile conditions after reconstitution. 		





Human IL-36β/IL-1F8 Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: AF1099

BACKGROUND

Human interleukin 1 family member #8 [IL-1F8; also named Interleukin-36 beta, IL36B, FIL-1η (eta) and IL-1H2] is a member of the IL-1 family of proteins (1-3). IL-1 family members include IL-1β, IL-1α, IL-18 and IL-1F5 through F10 (4). All family members show a 12 β-stranded β-trefoil configuration, and are believed to have arisen from a common ancestral gene that has undergone multiple duplications (4). Two alternatively spliced transcript variants encode distinct (164 or 157 residues) protein isoforms that differ in their C-terminal 70 amino acid (aa) residues have been reported (3). IL-1F8 isoform 2 is synthesized as a 157 aa protein that contains no signal sequence and no prosegment (1, 2). Unlike IL-1F8 isoform 1 which lacks potential N-linked glycosylation sites, isoform 2 contains one potential N-linked glycosylation site in its unique C-terminus. IL-1F8 is reported to be actively secreted (1). Human IL-1F8 isoform 2 shares 61% aa identity with mouse IL-1 ra, a 183 aa form of IL-1F8. Within the IL-1 family, IL-1F8 shares 30%, 32%, 37%, 46%, 34%, 45% and 28% aa sequence identity with IL-1 ra, IL-1β, IL-1F5, F6, F7, F9 and F10, respectively. Cells reported to express IL-1F8 include resting and activated monocytes and B cells (1, 4). The receptor for IL-1F8 is reported to be a combination of IL-1 Rrp2 and IL-1 RACP (5). Recombinant IL-1F8, along with IL-1F6 and IL-1F9, has been shown to activate the pathway involving NF-κB and MAPK in an IL-1 Rrp2 dependent manner.

References:

- 1. Smith, D.E. et al. (2000) J. Biol. Chem. 275:1169.
- 2. Kumar, S. et al. (2000) J. Biol. Chem. 275:10308.
- 3. Nicklin, M.J.H. et al. (2002) Genomics 79:718.
- 4. Dunn, E. et al. (2001) Trends Immunol. 22:533.
- 5. Towne, J.E. et al. (2004) J. Biol. Chem. 279:13677.

RED SYSTEMS